Yeshavanth Kumar Banasavadi-Siddegowda, Sriya Namagiri, Yoshihiro Otani, Hannah Sur, Sarah Rivas, Jean-Paul Bryant, Allison Shellbourn, Mitchell Rock, Ashis Chowdhury, Cole T Lewis, Toshihiko Shimizu, Stuart Walbridge, Sivarajan Kumarasamy, Ashish H Shah, Tae Jin Lee, Dragan Maric, Yuanqing Yan, Ji Young Yoo, Sangamesh G Kumbar, John D Heiss, Balveen Kaur
Background: The prognosis of glioblastoma (GBM) remains dismal because therapeutic approaches have limited effectiveness. A new targeted treatment using MEK inhibitors, including trametinib, has been proposed to improve GBM therapy. Trametinib had a promising preclinical effect against several cancers, but its adaptive treatment resistance precluded its clinical translation in GBM. Previously, we have demonstrated that protein arginine methyltransferase 5 (PRMT5) is upregulated in GBM and its inhibition promotes apoptosis and senescence in differentiated and stem-like tumor cells, respectively...
January 2022: Neuro-oncology advances